Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Senna glycosides, also known as sennosides, are stimulant laxatives derived from the *Senna* plant. SDA Laboratories markets a generic oral tablet formulation, branded as Senna Tabs, containing 8.6 mg of sennosides for the treatment of occasional constipation. As prodrugs, sennosides pass through the upper gastrointestinal tract unchanged and are hydrolyzed by colonic bacteria into active anthrone metabolites, such as rheinanthrone. These metabolites exert their therapeutic effect by irritating the colonic mucosa and stimulating the myenteric plexus (Auerbach's plexus), which leads to increased peristaltic activity and enhanced secretion of water and electrolytes into the intestinal lumen. This dual action facilitates bowel movements and provides effective relief from constipation. The product is an FDA-approved over-the-counter (OTC) medication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on senna glycosides.